What is Optifucin?
Optifucin is a substance that is used to treat bacterial infections. It will not work for colds, flu, or other virus infections.
Optifucin is available only with your doctor's prescription.
Optifucin indications
Optifucin is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Corynebacterium species, most clostridium species. Optifucin has no useful activity against enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila and Bacteroides fragilis). Optifucin is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.
One important use of Optifucin clinically is its activity against methicillin-resistant Staphylococcus aureus. Many strains of MRSA remain sensitive to Optifucin, but because there is a low genetic barrier to drug resistance (a single point mutation is all that is required), Optifucin must never be used on its own to treat serious MRSA infection and should be combined with another antimicrobial such as rifampicin.
Optifucin is often found in topical skin and eye preparations (e.g., Fucibet), a use which has been contested.
Uses of Optifucin in details
Optifucin is used for treating various bacterial skin infections and some infections of bone, heart, lungs and eyes.
Optifucin description
Optifucin is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Optifucin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
Optifucin dosage
Cream/Ointment: Apply to the affected area 2-3 times a day, generally for a period of 7 days.
Optifucin ointment can be used with or without a covering dressing.
Optifucin interactions
Optifucin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Optifucin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs. There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.
Optifucin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported.
Patients receiving concomitant lovastatin and erythromycin should be carefully monitored; cases of rhabdomyolysis have been reported in seriously ill patients.
Optifucin side effects
See also:
What are the possible side effects of Optifucin?
Occasionally hypersensitivity reactions eg, skin rashes, weak pain and irritation may occur. If these symptoms occur, discontinue Optifucin.
Optifucin contraindications
Optifucin is contraindicated in patients with known hypersensitivity to this antibiotic. Optifucin is contraindicated in patients taking terfenadine, astemizole, or cisapride.
Topical Ery 2% Pads are contraindicated in those individuals who have shown hypersensitivity to any of its components.
Active ingredient matches for Optifucin:
Fusidic Acid in Oman.
List of Optifucin substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| NOBOYLE (India) | |
| Noboyle 2% CRM / 10g (Neiss Labs Pvt. Ltd.) | $ 0.72 |
| Optifucin 1% (Egypt) | |
| Pharmaniaga Fusidic (Malaysia) | |
| Pharmaniaga Fusidic 2 % x 15 g (Pharmaniaga Manufacturing Berhad) | $ 0.00 |
| Pharmaniaga Fusidic cream 2 % 15 g x 1's (Pharmaniaga Manufacturing Berhad) | |
| Pharmaniaga Fusidic oint 2 % 15 g x 1's (Pharmaniaga Manufacturing Berhad) | $ 0.29 |
| Phucidin (China) | |
| Phudicin (China, Hong Kong) | |
| Phudicin / tube 10 g (Bright Future Pharm) | |
| Phudicin / container 450 g (Bright Future Pharm) | |
| Phudicin cream / tube 10 g x 1's (Bright Future Pharm) | |
| Phudicin cream / container 450 g x 1's (Bright Future Pharm) | |
| Qualifutin (Hong Kong) | |
| Qualifutin 2 % x 500 g (Quality) | $ 486.00 |
| Ramycin | |
| Robisid (Turkey) | |
| SAMADIC (India) | |
| 20 mg x 10g (Esma Formulations) | $ 1.08 |
| Samadic 20mg CRM / 10g (Esma Formulations) | $ 1.08 |
| Samadic Skin 10 gm Cream (Esma Formulations) | $ 1.08 |
| SAMADIC cream 20 mg x 10g (Esma Formulations) | $ 1.08 |
| Samadic 20mg CRM / 10g (Esma Formulations) | $ 1.08 |
| Shinsox Viscour (Taiwan) | |
| Shinsox Viscour 10 mg/1 mL x 5 mL | |
| Sodate Ointment (Bangladesh) | |
| Sofinox (India) | |
| Sofinox 2% CRM / 10g (Skinnova (Apex Laboratories Limited)) | $ 0.95 |
| Sofinox 2% CRM / 5g (Skinnova (Apex Laboratories Limited)) | $ 0.54 |
| Sofinox Skin 10 gm Cream (Skinnova (Apex Laboratories Limited)) | $ 0.10 |
| Sofinox Skin 5 gm Cream (Skinnova (Apex Laboratories Limited)) | $ 0.11 |
| SOFINOX CREAM 1 tube / 10 GM cream each (Skinnova (Apex Laboratories Limited)) | $ 1.20 |
| SOFINOX CREAM 1 tube / 5 GM cream each (Skinnova (Apex Laboratories Limited)) | $ 0.72 |
| SOFINOX CREAM 1 tube / 30 GM cream each (Skinnova (Apex Laboratories Limited)) | $ 3.37 |
| Sofinox cream 2% w/w 5 g x 1's (Skinnova (Apex Laboratories Limited)) | $ 5.87 |
| SOFINOX cream 2 % x 10g (Skinnova (Apex Laboratories Limited)) | $ 0.95 |
| SOFINOX cream 2 % x 5g (Skinnova (Apex Laboratories Limited)) | $ 0.54 |
| Sofinox 2% w/w Cream (Skinnova (Apex Laboratories Limited)) | $ 3.37 |
| Sofuni (Taiwan) | |
| Sofuni 2 % x 1 g | |
| Sofuni 2 % x 5 g | |
| Sofuni 2 % x 8 g | |
| Sofuni 2 % x 10 g | |
| Sofuni 2 % x 15 g | |
| Stafoban (India) | |
| Stafoban 2% OINT / 10g (Gratia (Micro Labs Ltd)) | $ 0.72 |
| 2 % x 10g (Gratia (Micro Labs Ltd)) | $ 0.72 |
| Stafoban Skin 10 gm Ointment (Gratia (Micro Labs Ltd)) | $ 0.72 |
| STAFOBAN 2% OINTMENT 1 tube / 15 GM ointment each (Gratia (Micro Labs Ltd)) | $ 0.78 |
| STAFOBAN oint 2 % x 10g (Gratia (Micro Labs Ltd)) | $ 0.72 |
| Stafoban 2% Ointment (Gratia (Micro Labs Ltd)) | $ 0.05 |
See 709 substitutes for Optifucin | |
References
- PubChem. "fusidic acid". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "fusidic acid". http://www.drugbank.ca/drugs/DB02703 (accessed September 17, 2018).
- DTP/NCI. "fusidic acid: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Optifucin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Optifucin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
